<DOC>
	<DOCNO>NCT00482807</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy deliver high- dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Androgens cause growth prostate cancer cell . Antihormone therapy , goserelin bicalutamide , may lessen amount androgen make body . Giving radiation therapy together chemotherapy hormone therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel give together intensity-modulated radiation therapy hormone therapy treat patient high-risk locally advanced prostate cancer pelvic lymph node metastasis .</brief_summary>
	<brief_title>Intensity-Modulated Radiation Therapy , Docetaxel , Hormone Therapy Treating Patients With High-Risk Locally Advanced Prostate Cancer With Pelvic Lymph Node Metastasis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine , preliminarily , grade III IV toxicity rate concurrent extended-field intensity-modulated radiotherapy ( IMRT ) , docetaxel , androgen deprivation therapy patient high-risk , locally advanced prostate cancer pelvic lymph node metastasis . Secondary - Determine , preliminarily , progression-free survival patient treat regimen . - Determine maximum tolerate dose docetaxel administer concurrent IMRT patient . OUTLINE : This dose-escalation study docetaxel . Patients receive combine androgen deprivation therapy ( already combine hormonal therapy ) comprise goserelin acetate* subcutaneously every 3 month 2 year oral bicalutamide daily begin day 1 continue completion radiotherapy . Beginning approximately week 9 androgen deprivation therapy , patient receive docetaxel IV 1 hour weekly 9 week . Concurrently chemotherapy , patient undergo intensity-modulated radiotherapy 5 day week 45 fraction ( 9 week ) . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . NOTE : *Not required patient undergone bilateral orchiectomy After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Locally advance disease ( T1 T3b , N1 N2 , M0 ) high risk recurrence Biopsyproven pelvic lymph node involvement No T4 lesion Prior androgen suppression within past 14 month allow provide follow criterion meet : No biochemical evidence PSA progression androgen withdrawal PSA progression , define 2 consecutive rise PSA value &gt; 4.0 ng/mL take ≥ 2 week apart No evidence distant metastasis , include follow : Bone metastasis Pathologic radiographic evidence lymph node involvement L4 L5 interspace PATIENT CHARACTERISTICS : Karnofsky performance status 80100 % ANC ≥ 1,500/mm³ Hemoglobin ≥ 10 g/dL Platelet count &gt; 100,000/mm³ Bilirubin normal Fertile patient must use effective contraception ≥ 3 month completion study treatment Meets 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal No peripheral neuropathy &gt; grade 1 No significant comorbidity would preclude radiotherapy No prior malignancy except nonmelanoma skin cancer cancer patient diseasefree past 5 year No hypersensitivity docetaxel drug formulate polysorbate 80 No history Crohn 's disease , ulcerative colitis , irritable bowel syndrome No unrepaired inguinal hernia PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior pelvic abdominal radiotherapy prostate brachytherapy implant No prior prostatectomy No prior pelvic abdominal surgery result excessive amount small intestine locate within pelvis No concurrent investigational agent</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>